IVD pricing and reimbursement are among the most strategically consequential and least understood forces shaping laboratory test volumes, supplier revenues, and competitive market positions globally. In the U.S., the Protecting Access to Medicare Act and the Clinical Laboratory Fee Schedule govern reimbursement for the majority of outpatient laboratory tests — and PAMA rate cuts have compressed laboratory margins and accelerated consolidation among independent labs. In October 2024, CMS announced expanded coverage of molecular diagnostics under the Clinical Laboratory Fee Schedule, supporting uptake of PCR-based respiratory panels and pharmacogenomic assays. In Europe, reimbursement is determined country by country — creating a fragmented landscape where the same test can command 10x different reimbursement rates across EU member states. Understanding this landscape is essential for market access strategy, pricing decisions, and forecasting test volumes by country.
Topics Covered
• IVD Pricing and Reimbursement Overview — Global Framework and Key Markets
• U.S. PAMA and Clinical Laboratory Fee Schedule — Rate History, Current Status, and Forecast
• CMS Coverage Decisions — Molecular Diagnostics, NGS, Liquid Biopsy, and Companion Diagnostics
• European Reimbursement — HTA Frameworks, National Coverage Decisions, and Country Analysis
• Asia-Pacific Reimbursement — Japan NHI, China NRDL, Australia MBS, and Key Markets
• Emerging Market Reimbursement — Brazil, India, Middle East, and Access Strategies
• Value-Based Reimbursement — Health Economics, QALY Models, and Payer Negotiation
• Companion Diagnostic Reimbursement — FDA/EMA Approval Pathways and Payer Acceptance
• Reimbursement Strategy — Pricing, Coding, and Coverage for New IVD Products
• Impact on Test Volumes and Supplier Revenues — Country-Level Analysis
'
Table of Contents
1. Executive Summary
- Key findings and strategic implications
- Most significant reimbursement developments 2024-2025
- Strategic recommendations
2. Global Reimbursement Framework Overview
- Key reimbursement systems and their market impact
- Reimbursement as a market access barrier and commercial driver
3. U.S. PAMA and Clinical Laboratory Fee Schedule
- PAMA rate history and current status
- Scheduled rate revisions and impact forecast
- CMS coverage decisions — molecular diagnostics, NGS, and liquid biopsy
4. European Reimbursement
- HTA frameworks and national coverage decision processes
- Country-by-country analysis — Germany, France, UK, Italy, Spain
- Eastern European reimbursement dynamics
5. Asia-Pacific Reimbursement
- Japan NHI pricing revisions and commercial implications
- China NRDL listing process and coverage dynamics
- Australia Medicare Benefits Schedule
6. Emerging Market Reimbursement
- Brazil and Latin America reimbursement frameworks
- India and Middle East access pricing strategies
- Global health program-funded testing
7. Value-Based Reimbursement
- Health economics models and QALY-based payer negotiations
- Evidence requirements for novel IVD test coverage
- Outcomes-based contracting models
8. Companion Diagnostic Reimbursement
- FDA and EMA co-development pathway and reimbursement linkage
- Payer acceptance of companion diagnostics
- Reimbursement strategy for precision oncology tests
9. Strategic Recommendations
- Pricing, coding, and coverage strategy for new IVD products
- Market entry sequencing by reimbursement landscape
- Advocacy and policy engagement strategies
10. Appendix
- Research methodology
- Abbreviations and definitions
- List of tables and figures
List of Tables
Table 1. U.S. Clinical Laboratory Fee Schedule — Rate History and Current Status
Table 2. CMS Coverage Decisions — Molecular Diagnostics and NGS 2023-2025
Table 3. European IVD Reimbursement Rates by Country and Test Category 2025
Table 4. Japan NHI Pricing — IVD Test Categories and Recent Revisions
Table 5. China NRDL — IVD Listing Status and Coverage Analysis 2025
Table 6. Australia Medicare Benefits Schedule — IVD Test Coverage 2025
Table 7. Emerging Market Reimbursement — Brazil, India, and Middle East 2025
Table 8. Health Economics Models — QALY and Cost-Effectiveness Thresholds by Country
Table 9. Companion Diagnostic Reimbursement — Coverage Status by Drug and Test 2025
Table 10. Strategic Reimbursement Framework — Market Entry Prioritization by Country
Abbott Diagnostics
Bio-Rad Laboratories
bioMérieux
Danaher (Beckman Coulter, Cepheid, Radiometer)
DiaSorin
Hologic
QuidelOrtho
Roche Diagnostics
Siemens Healthineers
Sysmex
